FDA’s Zuckerman Warns Against Inventor Involvement In Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Inventors should have minimal involvement in early clinical trials of their own technology, according to FDA's top cardiovascular device reviewer